$1.51
0.00%
Nasdaq, Fri, Sep 06 2024
ISIN
US00847L1008
Symbol
AGRX
Sector
Industry

Key metrics

Market capitalization $10.43m
Enterprise Value $7.87m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.36
P/S ratio (TTM) P/S ratio 0.48
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 32.21%
Revenue (TTM) Revenue $21.57m
EBIT (operating result TTM) EBIT $-13.55m
Free Cash Flow (TTM) Free Cash Flow $-1.71m
Cash position $2.85m
EPS (TTM) EPS $-3.23
P/S forward 0.28
EV/Sales forward 0.21
Short interest 7.50%
Show more

Is Agile Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Agile Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Agile Therapeutics, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Agile Therapeutics, Inc.:

Buy
100%

Financial data from Agile Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
22 22
32% 32%
100%
- Direct Costs 7.84 7.84
6% 6%
36%
14 14
54% 54%
64%
- Selling and Administrative Expenses 25 25
22% 22%
116%
- Research and Development Expense 1.79 1.79
31% 31%
8%
-13 -13
49% 49%
-61%
- Depreciation and Amortization 0.40 0.40
26% 26%
2%
EBIT (Operating Income) EBIT -14 -14
48% 48%
-63%
Net Profit -16 -16
52% 52%
-73%

In millions USD.

Don't miss a Thing! We will send you all news about Agile Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Agile Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about one month ago
Agile Therapeutics has combined with Insud Pharma's US Subsidiary, Exeltis USA, Inc., expanding an already significant women's health/contraceptive portfolio
Neutral
GlobeNewsWire
about 2 months ago
Dublin, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The "Agile Leadership for Pharma and Biopharma Professionals in a hybrid world Training Course" conference has been added to ResearchAndMarkets.com's offering.
Neutral
Business Wire
3 months ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Agile Therapeutics, Inc. (OTC: AGRX) to Insud Pharma, S.L. Under the terms of the proposed transaction, shareholders of Agile will receive $1.52 in cash for each share of Agile that they own. KSF is seeking to det...
More Agile Therapeutics, Inc. News

Company Profile

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

Head office United States
CEO Robert Spina
Employees 19
Founded 1997
Website www.agiletherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today